Studieoverzicht - 2022-04 NABOR
| Number | 2022-04 NABOR | ||||
| Nickname | NABOR | ||||
| Status | Open | Date: 01-03-2023 | |||
| Inclusion closed | |||||
| Other study number(s) | niet WMO | ||||
| Participating parties/groups | IKNL-UT-NIVEL | ||||
| Full title | Effectiveness of persoNalized care After treatment for non-metastasized Breast cancer based On risk of Recurrence, personal needs and risk on (late) health effects: the NABOR study. | ||||
| Phase and type | Other | ||||
| Age | ≥18 | ||||
| Menopausal status | Both pre- and postmenopausal | ||||
| Indication | Data registration | ||||
| Subindication | Any HER2, any HR | ||||
| Target sample size | 1040 | ||||
| Actual accrual | 0 | Date: 15-02-2023 | |||
| Estimated study completion date | |||||
| CCMO approval | Not applicable | Date: | Nr: | ||
| EudraCT nr. | |||||
| Trial Register | |||||
| METC approval | Not applicable | Date: | METC: | Nr: | |
| Amendments | Date: | ||||
| KWF-CKS approval | Date: | Nr: | |||
| News item | |||||
| Website | https://www.zonmw.nl/nl/onderzoek-resultaten/doelmatigheidsonderzoek/programmas/project-detail/evaluatieonderzoek-zegg/effectiveness-of-personalized-care-after-treatment-for-non-metastasized-breast-cancer-based-on-risk/ | ||||
| Sponsor | IKNL | ||||
| Principal Investigator(s) | Prof. dr. S. Siesling (IKNL, UT), dr. J.C. Korevaar (NIVEL) | |||
| Study manager | Anneleen Klaassen-Dekker; e-mail: NABOR@iknl.nl Beau Blokker, Projectmedewerker BOOG, info@boogstudycenter.nl |
|||
| Central datamanagement and randomization | PROFIEL | |||
| Monitoring | ||||
| Local datamanagement | NKR-IKNL | |||
| Funding | ZEGG | |||
| Extra | ||||
Design:
Objectives:
Endpoints:
Main eligibility criteria:
Documents (public):
Back